Schwartz Investment Counsel Inc. Has $49.71 Million Stock Position in Chemed Corporation $CHE

Schwartz Investment Counsel Inc. lowered its position in Chemed Corporation (NYSE:CHE) by 20.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,033 shares of the company’s stock after selling 28,771 shares during the quarter. Chemed makes up approximately 1.7% of Schwartz Investment Counsel Inc.’s holdings, making the stock its 17th biggest position. Schwartz Investment Counsel Inc. owned about 0.76% of Chemed worth $49,714,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Creekmur Asset Management LLC bought a new stake in shares of Chemed in the 2nd quarter valued at approximately $28,000. First Horizon Corp bought a new position in shares of Chemed during the 3rd quarter valued at $31,000. Parkside Financial Bank & Trust raised its holdings in shares of Chemed by 86.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after purchasing an additional 44 shares in the last quarter. HM Payson & Co. lifted its stake in shares of Chemed by 35.5% in the 3rd quarter. HM Payson & Co. now owns 103 shares of the company’s stock valued at $46,000 after purchasing an additional 27 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after purchasing an additional 76 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Chemed

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $437.55, for a total transaction of $875,100.00. Following the transaction, the chief executive officer owned 94,197 shares of the company’s stock, valued at approximately $41,215,897.35. The trade was a 2.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.29% of the company’s stock.

Chemed Stock Performance

Shares of NYSE:CHE opened at $452.40 on Monday. The company has a market cap of $6.41 billion, a P/E ratio of 23.92, a P/E/G ratio of 2.20 and a beta of 0.44. The stock’s 50-day moving average is $435.69 and its 200-day moving average is $443.85. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). The business had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.Chemed’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts predict that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Monday, November 17th were paid a $0.60 dividend. The ex-dividend date was Monday, November 17th. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is presently 12.69%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CHE. Royal Bank Of Canada cut their target price on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Finally, Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $574.25.

Chemed Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.